TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Thongprasert, S. AU - Yang, C. H. AU - Chu, D. T. AU - Saijo, N. AU - Sunpaweravong, P. AU - Han, B. AU - Margono, B. AU - Ichinose, Y. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Maemondo, M. AU - Inoue, A. AU - Kobayashi, K. AU - Sugawara, S. AU - Oizumi, S. AU - Isobe, H. AU - Gemma, A. AU - Harada, M. AU - Yoshizawa, H. AU - Kinoshita, I. PY - 2010 DA - 2010// TI - Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909530 DO - 10.1056/NEJMoa0909530 ID - Maemondo2010 ER - TY - JOUR AU - Mitsudomi, T. AU - Morita, S. AU - Yatabe, Y. AU - Negoro, S. AU - Okamoto, I. AU - Tsurutani, J. AU - Seto, T. AU - Satouchi, M. AU - Tada, H. AU - Hirashima, T. PY - 2010 DA - 2010// TI - Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial JO - The Lancet Oncol. VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70364-X DO - 10.1016/S1470-2045(09)70364-X ID - Mitsudomi2010 ER - TY - JOUR AU - Zhou, C. AU - Wu, Y. L. AU - Chen, G. AU - Feng, J. AU - Liu, X. Q. AU - Wang, C. AU - Zhang, S. AU - Wang, J. AU - Zhou, S. AU - Ren, S. PY - 2011 DA - 2011// TI - Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study JO - The Lancet Oncol. VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70184-X DO - 10.1016/S1470-2045(11)70184-X ID - Zhou2011 ER - TY - JOUR AU - Rosell, R. AU - Carcereny, E. AU - Gervais, R. AU - Vergnenegre, A. AU - Massuti, B. AU - Felip, E. AU - Palmero, R. AU - Garcia-Gomez, R. AU - Pallares, C. AU - Sanchez, J. M. PY - 2012 DA - 2012// TI - Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial JO - The Lancet Oncol. VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70393-X DO - 10.1016/S1470-2045(11)70393-X ID - Rosell2012 ER - TY - JOUR AU - Gazdar, A. F. PY - 2009 DA - 2009// TI - Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors JO - Oncogene VL - 28 UR - https://doi.org/10.1038/onc.2009.198 DO - 10.1038/onc.2009.198 ID - Gazdar2009 ER - TY - JOUR AU - Park, K. AU - Tan, E. H. AU - O'Byrne, K. AU - Zhang, L. AU - Boyer, M. AU - Mok, T. AU - Hirsh, V. AU - Yang, J. C. AU - Lee, K. H. AU - Lu, S. PY - 2016 DA - 2016// TI - Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial JO - The Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30033-X DO - 10.1016/S1470-2045(16)30033-X ID - Park2016 ER - TY - STD TI - Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncol. 2017; ID - ref8 ER - TY - JOUR AU - Tan, C. S. AU - Gilligan, D. AU - Pacey, S. PY - 2015 DA - 2015// TI - Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer JO - The Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00246-6 DO - 10.1016/S1470-2045(15)00246-6 ID - Tan2015 ER - TY - JOUR AU - Stewart, E. L. AU - Tan, S. Z. AU - Liu, G. AU - Tsao, M. S. PY - 2015 DA - 2015// TI - Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review JO - Translational lung cancer research VL - 4 ID - Stewart2015 ER - TY - JOUR AU - Morgillo, F. AU - Della Corte, C. M. AU - Fasano, M. AU - Ciardiello, F. PY - 2016 DA - 2016// TI - Mechanisms of resistance to EGFR-targeted drugs: lung cancer JO - ESMO open VL - 1 UR - https://doi.org/10.1136/esmoopen-2016-000060 DO - 10.1136/esmoopen-2016-000060 ID - Morgillo2016 ER - TY - JOUR AU - Yu, H. A. AU - Arcila, M. E. AU - Rekhtman, N. AU - Sima, C. S. AU - Zakowski, M. F. AU - Pao, W. AU - Kris, M. G. AU - Miller, V. A. AU - Ladanyi, M. AU - Riely, G. J. PY - 2013 DA - 2013// TI - Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2246 DO - 10.1158/1078-0432.CCR-12-2246 ID - Yu2013 ER - TY - JOUR AU - Tan, C. S. AU - Cho, B. C. AU - Soo, R. A. PY - 2016 DA - 2016// TI - Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer JO - Lung cancer (Amsterdam, Netherlands) VL - 93 UR - https://doi.org/10.1016/j.lungcan.2016.01.003 DO - 10.1016/j.lungcan.2016.01.003 ID - Tan2016 ER - TY - JOUR AU - Wang, S. AU - Cang, S. AU - Liu, D. PY - 2016 DA - 2016// TI - Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0268-z DO - 10.1186/s13045-016-0268-z ID - Wang2016 ER - TY - JOUR AU - Cross, D. A. AU - Ashton, S. E. AU - Ghiorghiu, S. AU - Eberlein, C. AU - Nebhan, C. A. AU - Spitzler, P. J. AU - Orme, J. P. AU - Finlay, M. R. AU - Ward, R. A. AU - Mellor, M. J. PY - 2014 DA - 2014// TI - AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer JO - Cancer discovery VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-14-0337 DO - 10.1158/2159-8290.CD-14-0337 ID - Cross2014 ER - TY - JOUR AU - Ballard, P. AU - Yates, J. W. AU - Yang, Z. AU - Kim, D. W. AU - Yang, J. C. AU - Cantarini, M. AU - Pickup, K. AU - Jordan, A. AU - Hickey, M. AU - Grist, M. PY - 2016 DA - 2016// TI - Preclinical comparison of Osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0399 DO - 10.1158/1078-0432.CCR-16-0399 ID - Ballard2016 ER - TY - JOUR AU - Janne, P. A. AU - Yang, J. C. AU - Kim, D. W. AU - Planchard, D. AU - Ohe, Y. AU - Ramalingam, S. S. AU - Ahn, M. J. AU - Kim, S. W. AU - Su, W. C. AU - Horn, L. PY - 2015 DA - 2015// TI - AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411817 DO - 10.1056/NEJMoa1411817 ID - Janne2015 ER - TY - JOUR AU - Goss, G. AU - Tsai, C. M. AU - Shepherd, F. A. AU - Bazhenova, L. AU - Lee, J. S. AU - Chang, G. C. AU - Crino, L. AU - Satouchi, M. AU - Chu, Q. AU - Hida, T. PY - 2016 DA - 2016// TI - Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study JO - The Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30508-3 DO - 10.1016/S1470-2045(16)30508-3 ID - Goss2016 ER - TY - STD TI - Goss G, Tsai C-M, Shepherd F, Ahn M-J, Bazhenova L, Crinò L, De Marinis F, Felip E, Morabito A, Hodge R, et al. MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials. J of Thoracic Oncol. 12(1):S440–1. ID - ref19 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. L. AU - Ahn, M. J. AU - Garassino, M. C. AU - Kim, H. R. AU - Ramalingam, S. S. AU - Shepherd, F. A. AU - He, Y. AU - Akamatsu, H. AU - Theelen, W. S. PY - 2017 DA - 2017// TI - Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung cancer JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1612674 DO - 10.1056/NEJMoa1612674 ID - Mok2017 ER - TY - STD TI - Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N Engl J Med. 2017, Nov 18; https://doi.org/10.1056/NEJMoa1713137 ePub ahead of print. ID - ref21 ER - TY - STD TI - Park K, Lee J-S, Lee KH, Kim J-H, Cho BC, Min YJ, Cho JY, Han J-Y, Kim B-S, Kim J-S, et al. BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D. J of Clin Oncol. 2016;34(15_suppl):9055–5. ID - ref22 ER - TY - STD TI - Boehringer Ingelheim returns development and commercial rights of olmutinib to Hanmi Pharmaceutical [https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-returns-development-commercial-rights-olmutinib-hanmi]. UR - https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-returns-development-commercial-rights-olmutinib-hanmi ID - ref23 ER - TY - STD TI - Ministry of Food and Drug Safety (South Korea). Safety report on olmutinib (article in Korean) [http://www.mfds.go.kr/index.do?mid=676&pageNo=1&seq=33700&cmd=v]. UR - http://www.mfds.go.kr/index.do?mid=676&pageNo=1&seq=33700&cmd=v ID - ref24 ER - TY - JOUR AU - Lelais, G. AU - Epple, R. AU - Marsilje, T. H. AU - Long, Y. O. AU - McNeill, M. AU - Chen, B. AU - Lu, W. AU - Anumolu, J. AU - Badiger, S. AU - Bursulaya, B. PY - 2016 DA - 2016// TI - Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and WT sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR mutants for the treatment of EGFR mutant non-small-cell lung cancers JO - J Med Chem VL - 59 UR - https://doi.org/10.1021/acs.jmedchem.5b01985 DO - 10.1021/acs.jmedchem.5b01985 ID - Lelais2016 ER - TY - STD TI - Tan DSW, Yang JCH, Leighl NB: Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016(3415(Suppl):abstr9044). ID - ref26 ER - TY - JOUR AU - Planken, S. AU - Behenna, D. C. AU - Nair, S. K. AU - Nagata, A. AU - Almaden, C. AU - Bailey, S. AU - Ballard, T. E. AU - Bernier, L. AU - Cheng, H. PY - 2017 DA - 2017// TI - Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H- purin-2-yl)pyrrolidine-3-yl) acrylamide (PF-06747775) through structure-based drug design: a high affinity irreversible inhibitor targeting oncogenic EGFR mutants with selectivity over wild-type EGFR JO - J Med Chem VL - 60 UR - https://doi.org/10.1021/acs.jmedchem.6b01894 DO - 10.1021/acs.jmedchem.6b01894 ID - Planken2017 ER - TY - STD TI - Husain H, Martins R, Goldberg S, Senico P, Ma W, Masters J, Pathan N, Kim D-W, Socinski M, Goldberg Z, et al. P3.02b-001 phase 1 dose escalation of PF-06747775 (EGFR-T790M inhibitor) in patients with advanced EGFRm (del 19 or L858R+/−T790M) NSCLC. J Thorac Oncol. 12(1):S1185. ID - ref28 ER - TY - JOUR AU - Xu, X. AU - Mao, L. AU - Xu, W. AU - Tang, W. AU - Zhang, X. AU - Xi, B. AU - Xu, R. AU - Fang, X. AU - Liu, J. AU - Fang, C. PY - 2016 DA - 2016// TI - AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients JO - Mol Cancer Ther VL - 15 UR - https://doi.org/10.1158/1535-7163.MCT-16-0281 DO - 10.1158/1535-7163.MCT-16-0281 ID - Xu2016 ER - TY - STD TI - Long Wu Y, Zhou Q, Liu X, Zhang L, Zhou J, Wu L, An T, Cheng Y, Zheng X, Hu B et al: MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation, vol. 12; 2017. ID - ref30 ER - TY - STD TI - Wang H, Zhang L, Zheng X, Zhang X, Si X, Wang M. The ability of avitinib to penetrate the blood brain barrier and its control of intra−/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation. J of Clin Oncol. 2017;35(15_suppl):e20613–3. ID - ref31 ER - TY - STD TI - Hong MH, Lee IY, Koh JS, Lee J, Suh B-C, Song H-J, Salgaonkar P, Lee J, Lee Y-S, Oh S-W, et al. P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC. J of Thoracic Oncol. 12(1):S1265–6. ID - ref32 ER - TY - STD TI - Clovis Oncology announces regulatory update for rociletinib NDA filing. Business Wire [http://www.businesswire.com/news/home/20151116005513/en/]. UR - http://www.businesswire.com/news/home/20151116005513/en ID - ref33 ER - TY - JOUR AU - Sequist, L. V. AU - Soria, J. C. AU - Camidge, D. R. PY - 2016 DA - 2016// TI - Update to Rociletinib data with the RECIST confirmed response rate JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMc1602688 DO - 10.1056/NEJMc1602688 ID - Sequist2016 ER - TY - STD TI - Goto Y, Nokihara H, Murakami H, Shimizu T, Seto T, Krivoshik AP, Keating AT, Uegaki K, Takeda K, Komatsu K, et al. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. J of Clin Oncol. 2015;33(15_suppl):8014–4. ID - ref35 ER - TY - STD TI - Yu HA, Spira AI, Horn L, Weiss J, West HJ, Giaccone G, Evans TL, Kelly RJ, Desai BB, Krivoshik A, et al. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study. 2016;J of Clinical Oncol, 34(15_suppl):9050–0. ID - ref36 ER - TY - STD TI - Astellas Announces Decision to Discontinue ASP8273 Treatment Arm and Close Randomization for Clinical Study Protocol 8273-CL-0302 [http://newsroom.astellas.us/2017-05-10-Astellas-Announces-Decision-to-Discontinue-ASP8273-Treatment-and-Close-Randomization-for-Clinical-Study-Protocol-8273-CL-0302]. UR - http://newsroom.astellas.us/2017-05-10-Astellas-Announces-Decision-to-Discontinue-ASP8273-Treatment-and-Close-Randomization-for-Clinical-Study-Protocol-8273-CL-0302 ID - ref37 ER - TY - STD TI - (Royal College of Physicians). National Lung Cancer Audit annual report 2016 (for the audit period 2015) [https://www.rcplondon.ac.uk/projects/outputs/nlca-annual-report-2016]. UR - https://www.rcplondon.ac.uk/projects/outputs/nlca-annual-report-2016 ID - ref38 ER - TY - JOUR AU - Wang, Z. AU - Chen, R. AU - Wang, S. AU - Zhong, J. AU - Wu, M. AU - Zhao, J. AU - Duan, J. AU - Zhuo, M. AU - An, T. AU - Wang, Y. PY - 2014 DA - 2014// TI - Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0110780 DO - 10.1371/journal.pone.0110780 ID - Wang2014 ER - TY - JOUR AU - Zheng, D. AU - Ye, X. AU - Zhang, M. Z. AU - Sun, Y. AU - Wang, J. Y. AU - Ni, J. AU - Zhang, H. P. AU - Zhang, L. AU - Luo, J. AU - Zhang, J. PY - 2016 DA - 2016// TI - Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep20913 DO - 10.1038/srep20913 ID - Zheng2016 ER - TY - JOUR AU - Hosokawa, M. AU - Hayata, T. AU - Fukuda, Y. AU - Arakaki, A. AU - Yoshino, T. AU - Tanaka, T. AU - Matsunaga, T. PY - 2010 DA - 2010// TI - Size-selective microcavity Array for rapid and efficient detection of circulating tumor cells JO - Anal Chem VL - 82 UR - https://doi.org/10.1021/ac101222x DO - 10.1021/ac101222x ID - Hosokawa2010 ER - TY - JOUR AU - Sundaresan, T. K. AU - Sequist, L. V. AU - Heymach, J. V. AU - Riely, G. J. AU - Janne, P. A. AU - Koch, W. H. AU - Sullivan, J. P. AU - Fox, D. B. AU - Maher, R. AU - Muzikansky, A. PY - 2016 DA - 2016// TI - Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1031 DO - 10.1158/1078-0432.CCR-15-1031 ID - Sundaresan2016 ER - TY - JOUR AU - Pailler, E. AU - Adam, J. AU - Barthelemy, A. AU - Oulhen, M. AU - Auger, N. AU - Valent, A. AU - Borget, I. AU - Planchard, D. AU - Taylor, M. AU - Andre, F. PY - 2013 DA - 2013// TI - Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.5932 DO - 10.1200/JCO.2012.44.5932 ID - Pailler2013 ER - TY - JOUR AU - Huang, W. L. AU - Chen, Y. L. AU - Yang, S. C. AU - Ho, C. L. AU - Wei, F. AU - Wong, D. T. AU - Su, W. C. AU - Lin, C. C. PY - 2017 DA - 2017// TI - Liquid biopsy genotyping in lung cancer: ready for clinical utility? JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.14613 DO - 10.18632/oncotarget.14613 ID - Huang2017 ER - TY - JOUR AU - Diaz, L. A. AU - Bardelli, A. PY - 2014 DA - 2014// TI - Liquid biopsies: genotyping circulating tumor DNA JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2012.45.2011 DO - 10.1200/JCO.2012.45.2011 ID - Diaz2014 ER - TY - JOUR AU - Thress, K. S. AU - Brant, R. AU - Carr, T. H. AU - Dearden, S. AU - Jenkins, S. AU - Brown, H. AU - Hammett, T. AU - Cantarini, M. AU - Barrett, J. C. PY - 2015 DA - 2015// TI - EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291 JO - Lung cancer (Amsterdam, Netherlands) VL - 90 UR - https://doi.org/10.1016/j.lungcan.2015.10.004 DO - 10.1016/j.lungcan.2015.10.004 ID - Thress2015 ER - TY - JOUR AU - Karlovich, C. AU - Goldman, J. W. AU - Sun, J. M. AU - Mann, E. AU - Sequist, L. V. AU - Konopa, K. AU - Wen, W. AU - Angenendt, P. AU - Horn, L. AU - Spigel, D. PY - 2016 DA - 2016// TI - Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of Rociletinib (CO-1686) JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1260 DO - 10.1158/1078-0432.CCR-15-1260 ID - Karlovich2016 ER - TY - JOUR AU - Ercan, D. AU - Choi, H. G. AU - Yun, C. H. AU - Capelletti, M. AU - Xie, T. AU - Eck, M. J. AU - Gray, N. S. AU - Janne, P. A. PY - 2015 DA - 2015// TI - EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2789 DO - 10.1158/1078-0432.CCR-14-2789 ID - Ercan2015 ER - TY - STD TI - Oxnard GR, Thress K, Paweletz C, Stetson D, Dougherty B, Markovets A, Janne PA: ORAL17.07 Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung Cancer. J of Thoracic Oncol 2015(10(9 Suppl.2); ORAL 17.07). ID - ref49 ER - TY - JOUR AU - Thress, K. S. AU - Paweletz, C. P. AU - Felip, E. AU - Cho, B. C. AU - Stetson, D. AU - Dougherty, B. AU - Lai, Z. AU - Markovets, A. AU - Vivancos, A. AU - Kuang, Y. PY - 2015 DA - 2015// TI - Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3854 DO - 10.1038/nm.3854 ID - Thress2015 ER - TY - JOUR AU - Song, H. N. AU - Jung, K. S. AU - Yoo, K. H. AU - Cho, J. AU - Lee, J. Y. AU - Lim, S. H. AU - Kim, H. S. AU - Sun, J. M. AU - Lee, S. H. AU - Ahn, J. S. PY - 2016 DA - 2016// TI - Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 11 UR - https://doi.org/10.1016/j.jtho.2015.12.093 DO - 10.1016/j.jtho.2015.12.093 ID - Song2016 ER - TY - JOUR AU - Chabon, J. J. AU - Simmons, A. D. AU - Lovejoy, A. F. AU - Esfahani, M. S. AU - Newman, A. M. AU - Haringsma, H. J. AU - Kurtz, D. M. AU - Stehr, H. AU - Scherer, F. AU - Karlovich, C. A. PY - 2016 DA - 2016// TI - Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms11815 DO - 10.1038/ncomms11815 ID - Chabon2016 ER - TY - STD TI - Tan DS-W, Kim D-W, Leighl NB, Riely GJ, Yang JC-H, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, et al. Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC). J of Clin Oncol. 2017;35(15_suppl):11506–6. ID - ref53 ER - TY - JOUR AU - Piotrowska, Z. AU - Niederst, M. J. AU - Karlovich, C. A. AU - Wakelee, H. A. AU - Neal, J. W. AU - Mino-Kenudson, M. AU - Fulton, L. AU - Hata, A. N. AU - Lockerman, E. L. AU - Kalsy, A. PY - 2015 DA - 2015// TI - Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor JO - Cancer discovery VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0399 DO - 10.1158/2159-8290.CD-15-0399 ID - Piotrowska2015 ER - TY - JOUR AU - Niederst, M. J. AU - Hu, H. AU - Mulvey, H. E. AU - Lockerman, E. L. AU - Garcia, A. R. AU - Piotrowska, Z. AU - Sequist, L. V. AU - Engelman, J. A. PY - 2015 DA - 2015// TI - The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0560 DO - 10.1158/1078-0432.CCR-15-0560 ID - Niederst2015 ER - TY - STD TI - Piotrowska Z, RJ N, Fairclough S, Lanman RB, Marcoux N, Gettinger SN, Owonikoko TK, Ramalingam SS, V. SL: OA 09.01- characterizing the genomic landscape of EGFR C797S in lung cancer using ctDNA next-generation sequencing. IASLC World Conference on Lung Cancer 2017. ID - ref56 ER - TY - JOUR AU - Menon, R. AU - Muller, J. AU - Schneider, P. AU - Lakis, S. AU - Thress, K. AU - Wolf, J. AU - Heukamp, L. AU - Heuckmann, J. M. AU - Griesinger, F. AU - Novel, A. PY - 2016 DA - 2016// TI - EGFR (C797) variant detected in a pleural biopsy specimen from an Osimertinib-treated patient using a comprehensive hybrid capture-based next-generation sequencing assay JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.04.005 DO - 10.1016/j.jtho.2016.04.005 ID - Menon2016 ER - TY - STD TI - Ou Q, Wu X, Bao H, Tong X, Wang X, Zhang X, Chang Z, Mao Y, Shao Y, Zhou C. Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. J Clin Oncol. 2017;35(15_suppl):2572–2. ID - ref58 ER - TY - JOUR AU - Ou, S. I. AU - Cui, J. AU - Schrock, A. B. AU - Goldberg, M. E. AU - Zhu, V. W. AU - Albacker, L. AU - Stephens, P. J. AU - Miller, V. A. AU - Ali, S. M. PY - 2017 DA - 2017// TI - Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib JO - Lung cancer (Amsterdam, Netherlands) VL - 108 UR - https://doi.org/10.1016/j.lungcan.2017.04.003 DO - 10.1016/j.lungcan.2017.04.003 ID - Ou2017 ER - TY - STD TI - Chen K, Zhou F, Shen W, Jiang T, Wu X, Tong X, Shao YW, Qin S, Zhou C. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. J of Thoracic Oncol. 12(6):e65–8. ID - ref60 ER - TY - JOUR AU - Bersanelli, M. AU - Minari, R. AU - Bordi, P. AU - Gnetti, L. AU - Bozzetti, C. AU - Squadrilli, A. AU - Lagrasta, C. A. AU - Bottarelli, L. AU - Osipova, G. AU - Capelletto, E. PY - 2016 DA - 2016// TI - L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.019 DO - 10.1016/j.jtho.2016.05.019 ID - Bersanelli2016 ER - TY - JOUR AU - Yam, I. AU - Lam, D. C. AU - Chan, K. AU - Chung-Man Ho, J. AU - Ip, M. AU - Lam, W. K. AU - Chan, T. K. AU - Chan, V. PY - 2012 DA - 2012// TI - EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 7 UR - https://doi.org/10.1097/JTO.0b013e3182558198 DO - 10.1097/JTO.0b013e3182558198 ID - Yam2012 ER - TY - JOUR AU - Cheng, C. AU - Wang, R. AU - Li, Y. AU - Pan, Y. AU - Zhang, Y. AU - Li, H. AU - Zheng, D. AU - Zheng, S. AU - Shen, X. AU - Sun, Y. PY - 2015 DA - 2015// TI - EGFR exon 18 mutations in east Asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, Clinicopathologic characteristics and prognosis JO - Sci Rep VL - 5 UR - https://doi.org/10.1038/srep13959 DO - 10.1038/srep13959 ID - Cheng2015 ER - TY - STD TI - Ramalingam SS, Yang JCH, Lee CK, Kurata T, Kim D-W, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, et al. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer. J of Clin Oncol. 2017; JCO.2017.2074.7576 ID - ref64 ER - TY - JOUR AU - Ortiz-Cuaran, S. AU - Scheffler, M. AU - Plenker, D. AU - Dahmen, L. AU - Scheel, A. H. AU - Fernandez-Cuesta, L. AU - Meder, L. AU - Lovly, C. M. AU - Persigehl, T. AU - Merkelbach-Bruse, S. PY - 2016 DA - 2016// TI - Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors JO - Clinical cancer research: an official journal of the American Association for Cancer Research VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1915 DO - 10.1158/1078-0432.CCR-15-1915 ID - Ortiz-Cuaran2016 ER - TY - JOUR AU - Eberlein, C. A. AU - Stetson, D. AU - Markovets, A. A. AU - Al-Kadhimi, K. J. AU - Lai, Z. AU - Fisher, P. R. AU - Meador, C. B. AU - Spitzler, P. AU - Ichihara, E. AU - Ross, S. J. PY - 2015 DA - 2015// TI - Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3167 DO - 10.1158/0008-5472.CAN-14-3167 ID - Eberlein2015 ER - TY - JOUR AU - Ho, C. C. AU - Liao, W. Y. AU - Lin, C. A. AU - Shih, J. Y. AU - Yu, C. J. AU - Chih-Hsin Yang, J. PY - 2017 DA - 2017// TI - Acquired BRAF V600E mutation as resistant mechanism after treatment with Osimertinib JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.2231 DO - 10.1016/j.jtho.2016.11.2231 ID - Ho2017 ER - TY - JOUR AU - Planchard, D. AU - Loriot, Y. AU - Andre, F. AU - Gobert, A. AU - Auger, N. AU - Lacroix, L. AU - Soria, J. C. PY - 2015 DA - 2015// TI - EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients JO - Annals of oncology: official journal of the European Society for Med Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv319 DO - 10.1093/annonc/mdv319 ID - Planchard2015 ER - TY - JOUR AU - Ou, S. I. AU - Agarwal, N. AU - Ali, S. M. PY - 2016 DA - 2016// TI - High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression JO - Lung cancer (Amsterdam, Netherlands) VL - 98 UR - https://doi.org/10.1016/j.lungcan.2016.05.015 DO - 10.1016/j.lungcan.2016.05.015 ID - Ou2016 ER - TY - STD TI - Piotrowska Z, Thress KS, Mooradian M, Heist RS, Azzoli CG, Temel JS, Rizzo C, Nagy RJ, Lanman RB, Gettinger SN, et al. MET amplification (amp) as a resistance mechanism to osimertinib. J of Clin Oncol. 2017;35(15_suppl):9020–0. ID - ref70 ER - TY - JOUR AU - Shi, P. AU - Oh, Y. T. AU - Zhang, G. AU - Yao, W. AU - Yue, P. AU - Li, Y. AU - Kanteti, R. AU - Riehm, J. AU - Salgia, R. AU - Owonikoko, T. K. PY - 2016 DA - 2016// TI - Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment JO - Cancer Lett VL - 380 UR - https://doi.org/10.1016/j.canlet.2016.07.021 DO - 10.1016/j.canlet.2016.07.021 ID - Shi2016 ER - TY - JOUR AU - Kim, T. M. AU - Song, A. AU - Kim, D. W. AU - Kim, S. AU - Ahn, Y. O. AU - Keam, B. AU - Jeon, Y. K. AU - Lee, S. H. AU - Chung, D. H. AU - Heo, D. S. PY - 2015 DA - 2015// TI - Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000688 DO - 10.1097/JTO.0000000000000688 ID - Kim2015 ER - TY - JOUR AU - Ham, J. S. AU - Kim, S. AU - Kim, H. K. AU - Byeon, S. AU - Sun, J. M. AU - Lee, S. H. AU - Ahn, J. S. AU - Park, K. AU - Choi, Y. L. AU - Han, J. PY - 2016 DA - 2016// TI - Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment JO - Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer VL - 11 UR - https://doi.org/10.1016/j.jtho.2015.09.013 DO - 10.1016/j.jtho.2015.09.013 ID - Ham2016 ER - TY - JOUR AU - Li, L. AU - Wang, H. AU - Li, C. AU - Wang, Z. AU - Zhang, P. AU - Yan, X. PY - 2017 DA - 2017// TI - Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: a case report JO - Oncotarget VL - 8 ID - Li2017 ER - TY - JOUR AU - Wang, S. AU - Song, Y. AU - Liu, D. PY - 2017 DA - 2017// TI - EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance JO - Cancer Lett VL - 385 UR - https://doi.org/10.1016/j.canlet.2016.11.008 DO - 10.1016/j.canlet.2016.11.008 ID - Wang2017 ER - TY - JOUR AU - Jia, Y. AU - Yun, C. H. AU - Park, E. AU - Ercan, D. AU - Manuia, M. AU - Juarez, J. AU - Xu, C. AU - Rhee, K. AU - Chen, T. AU - Zhang, H. PY - 2016 DA - 2016// TI - Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors JO - Nature VL - 534 UR - https://doi.org/10.1038/nature17960 DO - 10.1038/nature17960 ID - Jia2016 ER - TY - JOUR AU - Li, D. AU - Shimamura, T. AU - Ji, H. AU - Chen, L. AU - Haringsma, H. J. AU - McNamara, K. AU - Liang, M. C. AU - Perera, S. A. AU - Zaghlul, S. AU - Borgman, C. L. PY - 2007 DA - 2007// TI - Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy JO - Cancer Cell VL - 12 UR - https://doi.org/10.1016/j.ccr.2007.06.005 DO - 10.1016/j.ccr.2007.06.005 ID - Li2007 ER - TY - JOUR AU - Gunther, M. AU - Juchum, M. AU - Kelter, G. AU - Fiebig, H. AU - Laufer, S. PY - 2016 DA - 2016// TI - Lung cancer: EGFR inhibitors with low Nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant JO - Angewandte Chemie (International ed in English) VL - 55 UR - https://doi.org/10.1002/anie.201603736 DO - 10.1002/anie.201603736 ID - Gunther2016 ER - TY - JOUR AU - Gunther, M. AU - Lategahn, J. AU - Juchum, M. AU - Doring, E. AU - Keul, M. AU - Engel, J. AU - Tumbrink, H. L. AU - Rauh, D. AU - Laufer, S. PY - 2017 DA - 2017// TI - Trisubstituted Pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site JO - J Med Chem VL - 60 UR - https://doi.org/10.1021/acs.jmedchem.7b00316 DO - 10.1021/acs.jmedchem.7b00316 ID - Gunther2017 ER - TY - STD TI - Chic N, Mayo-de-las-Casas C, Reguart N. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib. J Thoracic Oncol. 12(6):e78–80. ID - ref80 ER - TY - JOUR AU - Wang, Z. AU - Yang, J. J. AU - Huang, J. AU - Ye, J. Y. AU - Zhang, X. C. AU - Tu, H. Y. AU - Han-Zhang, H. AU - Wu, Y. L. PY - 2017 DA - 2017// TI - Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.06.017 DO - 10.1016/j.jtho.2017.06.017 ID - Wang2017 ER - TY - STD TI - Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, Fujita N, Katayama R: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. 2017, 8:14768. ID - ref82 ER - TY - STD TI - Shi P, Oh YT, Deng L, Zhang G, Qian G, Zhang S, Ren H, Wu G, Legendre B Jr, Anderson E, et al. Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017; ID - ref83 ER - TY - JOUR AU - Martin, M. J. AU - Eberlein, C. AU - Taylor, M. AU - Ashton, S. AU - Robinson, D. AU - Cross, D. PY - 2016 DA - 2016// TI - Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.13388 DO - 10.18632/oncotarget.13388 ID - Martin2016 ER - TY - STD TI - Arbour KC, Sequist LV, Piotrowska Z, Kris MG, Paik PK, Ni A, Plodkowski A, Riely GJ, Yu HA. Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC. J Clin Oncol. 2017;35(15_suppl):e20673–3. ID - ref85 ER -